Copyright © Inderes 2011 - present. All rights reserved.

Nexstim

14.10 EUR

-0.70 %

5,596 following

NXTMH

First North Finland

Medical Equipment & Services

Health Care

-0.70 %
-4.73 %
+11.02 %
+38.24 %
+78.48 %
+114.94 %
+223.39 %
+169.59 %
-97.67 %

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

Read more
Market cap
101.71M EUR
Turnover
50.15K EUR
P/E (adj.) (25e)
24.96
EV/EBIT (adj.) (25e)
24.28
P/B (25e)
12.9
EV/S (25e)
6.58
Dividend yield-% (25e)
-
Coverage
Recommendation
Reduce
Target price
12.50 EUR
Updated
18.08.2025
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 18.08.2025

Latest extensive report

Released: 26.06.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
Added nexstim last week. Although no deals have been announced in December, I trust the company’s long-term story. The company is growing strongly this year and will also become solidly profitable at the EBIT level. In fact, the key figures will be among the elite of the Helsinki...
6 hours ago
by Tomi Lindell
28
I wonder if this Danish deal has been announced at all? The advent calendar might be seriously off. The only trade announcement this could match was from July, and I don’t believe in such a long delivery time. linkedin.com Such a great milestone and so impressed by the team at Privathospit...
3 hours ago
by Kyhnykeisari
19
2025’s Grand Finale: Inside the Best of Keiretsu Forum Virtual Investment Showcase linkedin.com 2025’s Grand Finale: Inside the Best of Keiretsu Forum Virtual Investment... In the final weeks of 2025, the US early-stage investment community turned its attention to one place: the ...
yesterday
by Jatast
13
Sinaptican funding round progresses: Sinaptica Therapeutics™ - Noninvasive Neuromodulation: A True Breakthrough in... – 11 Dec 25 Sinaptica Therapeutics Receives Funding from The Centre for Aging + Brain... Cambridge, MA – December 10, 2025 – Sinaptica Therapeutics, Inc., a clinical...
yesterday
by Tim89
11
I still live in the belief that those would also be announced. What would be Nexstim’s interest in keeping such a positive surprise under wraps? I stick to my position that a significant Brainlab deal will only start next year and will largely follow the previously stated 18-month...
12/9/2025, 4:51 PM
by Kyhnykeisari
9
Reaching Inderes’ estimate requires very brisk sales and also deliveries for this year, or alternatively, it requires that Brainlab has sold and Sinaptica has ordered devices that have not been announced. It would be nice to get clarified information from Nexstim regarding these ...
5 hours ago
by Jatast
7
Waiting can sometimes be long, but now it has felt exceptionally long for those of us who eagerly follow market news in the mornings. Good things are worth waiting for; we must keep that firmly in mind and not let uncertainty take hold. After all, the share price has risen by 7.60...
yesterday
by Pilkkionkija
6
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.